Upgrade our patented phytochemical compounds from plant extract, and make of them a true scientific promise, like successful biomedicines and nutraceutics in the market in order to address important solutions to clinic and nutritional needs.
The businessman Francisco Bermúdez Pérez, to value his collaboration with the Center for Biomedical Research (CIBM) of the University of Granada, founded the company with the aim of developing research aimed at the field of plant biology, to obtain phytochemical compounds with high antioxidant power and anti-cancer ability.
The company, after its initial capital investment, begins a detailed search of technologies developed in public centers and research institutes and in universities in Europe and Latin America.
As a result of the intense collaboration with the CIBM, four phytochemical compounds, of botanical origin, with a high antioxidant and anti-cancer activity are identified.
These promising results promote the creation of a joint research consortium, in which IFAPA is also incorporated, to deepen the R&D work …
In December 2018, the project “Vegetable Nano-nutraceuticals with antitumor activity against colon cancer” led by Cellbitec and in which the CIBM-UGR and IFAPA participate, gets the support of the State R&D&i Program, oriented to the Challenges of the Society.
This program has public funding from the ERDF funds of the European Union and is managed by the Ministry of Science, Innovation and Universities of the Government of Spain.
In March 2019, a Phd. Torres Quevedo team joins the Cellbitec team, to lead and strengthen the company’s own activities in the field of R&D and to coordinate the work carried out, in collaboration with the CIBM-UGR and the IFAPA.
This incorporation is carried out with the support of the State Program for the Promotion of Talent and its Employability in R&D&i, managed by the Ministry of Science, Innovation and Universities of the Government of Spain.
In 2019, the company made the decision to focus on the protection of intellectual and industrial property of both the bioactive phytochemical compounds of botanical origin that have been identified in the R&D work, as well as the methodology of biochemical synthesis of the molecules responsible for anticancer activity.
It also begins to develop its products with pharmaceutical and nutraceutical capacity…
The CELLBITEC team is further strengthened and an expansion phase begins, expanding its shareholder base through a round of Series A financing, preparing to begin the PHASE I clinical development of its plant-based phytochemicals, in order to validate the safety and toxicology results obtained in the PRECLINICAL PHASE.
While this work is being carried out, CELLBITEC starts the work to evaluate other possible indications of its phytochemical compounds, and to carry out studies of them applied for their potential application in the metabolic syndrome…
In Cellbitec we are focused on four very defined lines of business
Discover the Future
We are a biotechnological and pharmaceutical company with a strong sense of responsibility about medicine, nutraucetic and efficient bioactive principles discovery with natural origin in the plant biology area.